What Is the Right Revenue Mix for a Medical Spa?

A well-run single-location medical spa runs injectables at 55 to 65 percent of total revenue, devices and laser at 15 to 20 percent, facials and skin services at 10 to 15 percent, memberships at 5 to 10 percent, and retail at 3 to 7 percent. Practices outside these ranges are usually over-concentrating in one line, carrying an underperformer, or both.

Most owners know their total revenue number. Far fewer know how it splits by service line. That split is where margin problems hide.

For total revenue figures by practice tier, the med spa revenue benchmarks post has those numbers. This one covers what's inside them: what percentage each service line should contribute, and what a bad mix signals.

What service line revenue mix actually measures

Med spa service line revenue mix is the percentage of total practice revenue generated by each distinct service category, measured separately rather than as a blended total. Total revenue tells you what a practice collects. Service line mix tells you where it comes from, at what margin, and how exposed the practice is when one category slows down.

A practice at 78 percent injectables is a single-product business. The financial exposure and P&L opacity are the same as any business relying on one revenue source to cover fixed costs.

Two practices at identical annual revenue can carry very different margin profiles depending on how that revenue is split. One may carry a device lease that consumes most of its laser revenue. Another may run facials at a labor percentage that leaves nothing for profit. Neither problem appears on a blended revenue report.

Why your POS total is not the same as service line revenue

Every booking system produces a revenue total. Zenoti, Boulevard, AestheticsPro, and PatientNow all report one. That number is not the same as service line revenue for two reasons. First, most POS systems blend categories with different cost structures into a single clinical revenue line. Second, POS totals often include loyalty redemptions at full transaction value rather than net cash collected, which inflates whichever category processes the most loyalty activity. Injectables, where Alle and Aspire redemptions are common, take the biggest hit.

The med spa bookkeeping setup guide covers how to build the chart of accounts that separates these categories correctly in QuickBooks so the P&L reflects actual service line performance rather than blended POS totals.

Reading the benchmark table: what each column shows

Five service lines, each with a benchmark percentage, a gross margin range, and a warning signal. The margin ranges reflect correctly reconciled COGS: vendor product cost for injectables, device lease and consumables for laser, product cost for retail. Books that do not separate these cost lines show inflated margins. The COGS sits buried in a blended supply expense.

Practices that have added a weight management service line should track it separately from injectables. GLP-1 and semaglutide programs carry different COGS structure (compounded or brand drug pricing versus Allergan and Galderma vendor invoices) and different patient economics. Folding program revenue into the injectable line distorts both injectable margin and total service mix. For contribution benchmarks specific to weight management, see the GLP-1 program revenue benchmark guide.

Injectable services -- the anchor service line

Injectables represent the majority of revenue at most single-location medical spas. The 55 to 65 percent range reflects practices that have built other service lines alongside a strong injectable core. Below 55 percent typically signals underdeveloped injectable capacity or unusually high device volume. Above 65 percent means concentration in a single line, without the margin buffer diversification provides.

The gross margin on injectables, after Allergan, Galderma, Merz, Evolus, and Revance product costs, typically runs 60 to 70 percent for a well-run practice. The most common measurement error is recording injectable purchases as bulk supply expense rather than reconciling vendor invoices to individual service lines.

A practice doing that will show 80 to 85 percent injectable gross margin. Those numbers look strong but reflect missing data, not pricing efficiency. See the injectable gross margin guide for the step-by-step reconciliation.

Injectable revenue is seasonal. Most practices see a Q4 spike from Botox promotions and end-of-year patient spending, then a Q1 contraction as spending normalizes. At 70 percent injectable concentration, that swing hits hard. At 60 percent injectables with 20 percent in devices, the practice has more cushion during slow months.

When injectables exceed 65 percent of revenue

Concentration above 65 percent creates 3 specific risks that standard P&L reporting does not surface. Injectable revenue correlates directly with provider availability. When the primary injector is out, revenue exposure is immediate. A practice where 70 percent of revenue flows through one or two injectors carries key-person risk that does not appear on a balance sheet.

Injectable patients are also more likely to comparison-shop on price than membership or device patients who have pre-committed to a treatment sequence. High injectable concentration amplifies pricing pressure from competitors running promotions. Allergan and Galderma both adjust pricing and rebate structures. A practice at 75 percent injectable is more exposed to those changes than one with a more balanced mix.

When injectables fall below 50 percent of revenue

A practice with injectable revenue below 50 percent is either running strong device volume or has underdeveloped injectable capacity. Injectables carry better absolute gross margin than retail and better COGS transparency than laser when the books are correctly structured. A practice that should be running more injectable volume but is not should look at provider scheduling, front desk conversion from consultations, and treatment room capacity.

Laser and device treatments

Laser and device revenue should represent 15 to 20 percent of total revenue at a single-location practice with one or two devices. Below 10 percent, a device is not generating enough volume to cover its monthly lease. Above 25 percent is achievable for practices that have invested heavily in device capacity, but it requires watching break-even at the unit level.

Device economics make service line tracking essential. A monthly device lease runs $2,500 to $6,000 for most aesthetic equipment. That fixed cost has to be covered before a dollar of gross profit reaches the practice. At $9,000 per month in laser revenue against a $5,000 monthly lease, the device covers its fixed cost before accounting for consumables, provider time, and room overhead. Below that threshold, it is a cost center. See the device ROI calculator for the break-even formula. Device revenue has to be isolated as its own P&L line. A practice coding all clinical revenue to a single income account cannot run this calculation without manual extraction.

Device utilization and the 47 percent benchmark

Zenoti's 2025 Beauty and Wellness Benchmark Report puts average staff utilization at 47 percent across med spas. Top performers run at 78 percent. For a device with a fixed monthly lease, utilization is a direct revenue driver. Hours the device sits idle are hours the lease payment goes unrecovered. A practice at 47 percent utilization on a device that generates $9,000 per month at full capacity is collecting closer to $4,200 per month against the same fixed lease. When device revenue is isolated in the P&L alongside the device lease line item, this problem becomes visible in the monthly numbers, not at year-end after 12 months of the same pattern.

Facials and skin services

Facials and skin treatments typically represent 10 to 15 percent of revenue at a balanced single-location practice. COGS is low: most facial services use house-brand or private-label products that cost 10 to 20 percent of the service price. But margin depends heavily on provider utilization. An esthetician generating $300 per hour in facial revenue with a $50,000 annual compensation package is profitable. One generating $150 per hour on the same package is not, regardless of the low COGS.

Practices where facials exceed 20 percent of revenue often have an injectable capacity constraint. Providers are not available for the injectable demand the practice could capture, so revenue defaults to facials. That shift compresses margin because facials produce lower revenue per clinical hour than injectables.

When facial revenue drops below 8 percent, it usually reflects esthetician underutilization, not a pricing problem. The service exists but is not being sold. Retail attachment rates, rebooking rates for skin series, and front desk conversion behavior all drive this line more than pricing does.

Membership revenue

Memberships should represent 5 to 10 percent of revenue. Below 3 percent, the practice has no recurring revenue. Every month starts from zero. Above 12 to 15 percent, the membership structure may be more generous than the P&L supports, particularly if membership services are being delivered at a discount that compresses gross margin per visit.

Membership revenue has an accounting wrinkle the total revenue number obscures. When a patient pays for a monthly membership, cash is collected but not earned until the service is delivered. Most default bookkeeping setups record that payment as immediate revenue. The correct treatment creates a deferred revenue liability for unearned membership value. A practice with $60,000 in outstanding membership balances is overstating current-period revenue by that amount. See the membership revenue accounting guide for the QuickBooks setup.

Why membership concentration above 12 percent warrants review

A $199-per-month membership for unlimited facials may drive retention while delivering services at an effective hourly rate below clinical cost when a provider is fully booked with members. The membership revenue line looks consistent on the P&L. The margin it generates requires COGS and provider time data layered in. Practices with more than 12 percent of revenue in memberships should run a member-specific contribution margin analysis before expanding the program.

Retail

Retail sits at 3 to 7 percent of revenue for most practices. Below that, retail exists but is not driving revenue. Above 10 percent, the practice may be over-indexed to product sales in a way that makes total revenue look better than it is.

Retail gross margin runs 40 to 55 percent after product cost, lower than any clinical service category. A practice inflating retail revenue through aggressive markups shows strong total revenue with modest total margin because retail produces less gross profit per dollar than injectables or facials. Retail's real financial value is patient retention: someone who buys skincare at a med spa is more likely to rebook and upgrade to clinical services. A retail program without a rebooking strategy does not pay for its shelf space.

When retail exceeds 10 percent of revenue

Retail above 10 percent at a clinical med spa is worth examining. It may reflect a strong curation strategy with high sell-through. More often it reflects aggressive product pricing for volume, or a clinical revenue base smaller than it should be, making retail look large as a percentage. Pull retail COGS separately and calculate its gross margin against the clinical lines it is pulling provider time from.

How to calculate your service line revenue mix

This is a five-step process using POS data and your bookkeeping system. Most practices can complete it in one to two hours for a 90-day period. Run it quarterly. Monthly variance in a single line is usually noise. A 90-day pattern is signal.

1. 1
   Pull 90 days of revenue by service category from your POS. Zenoti, Boulevard, AestheticsPro, and PatientNow all produce this as a standard report. Export the category-level breakdown, not the blended total. You need revenue by category for the full 90-day period.
2. 2
   Map every POS category to one of the five service lines above. Some practices have 15 to 20 POS categories. Every one maps to injectables, laser and devices, facials and skin, memberships, or retail. Memberships go on their own line. Gift cards do not count until redeemed.
3. 3
   Calculate each line as a percentage of total revenue for the period. Divide each service line total by total revenue for the same 90 days. This gives you your current mix. Write it down next to the benchmark ranges from the table above.
4. 4
   Identify the line furthest from benchmark. One line is almost always the clear outlier -- either significantly above or below its range. That line is where the diagnostic work begins. If injectables are 75 percent, the next question is provider scheduling and capacity. If laser is 7 percent, the next question is device utilization versus lease cost.
5. 5
   Pull COGS separately for the outlier line and calculate its gross margin. For injectables, that means pulling Allergan, Galderma, Merz, and Evolus invoice totals for the same period and comparing to injectable revenue. For laser, pull device lease payments and consumable costs. The gross margin on the outlier line tells you whether the concentration is a strength or a structural problem.

The concentration risk most owners miss

The most common mix problem is not a single line dramatically out of range. It is a practice where injectables sit at 70 to 75 percent of revenue, laser at 7 to 9 percent, and facials at 4 to 5 percent. Each line individually looks close to normal. Together, they produce a business far more exposed to a single-quarter injectable slowdown than the revenue number suggests.

The worked example below uses a $1.4M practice with exactly this profile.

A 10 percent Q1 drop in injectable volume is normal for this industry. At 78 percent injectable concentration, that swing is $9,100 per month in lost revenue. At 60 percent concentration, the same Q1 drop produces $6,000 per month in lost revenue: $3,100 less exposure, with device and membership revenue partially absorbing the swing.